The UK’s Ashfield Healthcare Communications and Argon Global Healthcare Network have announced that they have combined their capabilities to assist clients with managing their brands in existing locations and expanding into new.
“The complementary service offerings and greater geographical reach from Ashfield and Argon will provide clients a non-holding company approach to the global environment. Collectively this partnership provides our clients with unprecedented agility and access to a full breadth of communications services tailored with a deep understanding of cultural and business nuances for their regional and local needs,” a press release reports.
Ashfield Healthcare Communications president Doug Burcin commented: “I am delighted with this partnership in that it continues to deliver on our approach to being a truly global micro network. We have a well-established presence in the UK, Germany, Japan and US for delivering our solutions at the intersection of science, data and creativity so we are excited to come together with the Argon Global Healthcare Network to be able to deliver this on an even more global scale.”
Doug Burcin
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.